- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 5
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 5, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 5.
Number 5: According to a new review of the literature, managed care professionals can help providers to personalize treatment for patients with macular degeneration, and can encourage adherence.
Number 4: A recent cross-sectional study found that the uptake of biosimilars in the United Kingdom has been highly variable and generally lower than expected.
Number 3: Sales of MabThera dropped sharply due to competition from biosimilars in the European Union.
Number 2: YL Biologics has reported positive phase 3 clinical trial results for its proposed biosimilar referencing Erelzi.
Number 1: The American College of Rheumatology has released a new white paper that supports the use of biosimilars in clinical practice.
Also this week, Dr Robert Levin, a practicing rheumatologist and patient advocate, wrote in The Center for Biosimilars® that, if HHS wants to confront the problem of high drug prices, it must address the growing role of pharmacy benefit managers.
Finally, last week, our e-newsletter asked whether physicians’ expectations of clinical trials are hindering biosimilar acceptance.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
